Nanjing Vishee Medical Technology Co., Ltd
Symboli: 688580.SS
SHH
47.44
CNYMarkkinahinta tänään
25.8198
P/E-suhde
0.0000
PEG-suhde
3.23B
MRK Cap
- 0.01%
DIV Tuotto
Nanjing Vishee Medical Technology Co., Ltd (688580-SS) Tilinpäätöstiedotteet
Tase
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 1155 | 1248.1 | 1366 | ||||||||||
balance-sheet.row.short-term-investments | 0 | 2266.4 | 0 | 0 | ||||||||||
balance-sheet.row.net-receivables | 0 | 47.3 | 31.9 | 36.7 | ||||||||||
balance-sheet.row.inventory | 0 | 39.9 | 34.8 | 30.4 | ||||||||||
balance-sheet.row.other-current-assets | 0 | 12.6 | 4.3 | 1.2 | ||||||||||
balance-sheet.row.total-current-assets | 0 | 1254.8 | 1319.2 | 1434.3 | ||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 321.5 | 172.5 | 100.3 | ||||||||||
balance-sheet.row.goodwill | 0 | 69.3 | 69.3 | 0 | ||||||||||
balance-sheet.row.intangible-assets | 0 | 120.6 | 106.5 | 18.8 | ||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 189.9 | 175.8 | 18.8 | ||||||||||
balance-sheet.row.long-term-investments | 0 | -2244.3 | 0 | 0.8 | ||||||||||
balance-sheet.row.tax-assets | 0 | 15.1 | 7.9 | 12.7 | ||||||||||
balance-sheet.row.other-non-current-assets | 0 | 2269 | 8.8 | 71.9 | ||||||||||
balance-sheet.row.total-non-current-assets | 0 | 551.2 | 365 | 204.4 | ||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-assets | 0 | 1806 | 1684.2 | 1638.7 | ||||||||||
balance-sheet.row.account-payables | 0 | 18 | 19.7 | 9.3 | ||||||||||
balance-sheet.row.short-term-debt | 0 | 0 | 1.2 | 1.2 | ||||||||||
balance-sheet.row.tax-payables | 0 | 19.6 | 21.1 | 29.3 | ||||||||||
balance-sheet.row.long-term-debt-total | 0 | 0 | 0 | 1.8 | ||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | ||||||||||
balance-sheet.row.other-current-liab | 0 | 133.7 | 94.8 | 1.6 | ||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 27.6 | 26.4 | 1.8 | ||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 1.2 | 1.8 | ||||||||||
balance-sheet.row.total-liab | 0 | 179.3 | 155.7 | 105.7 | ||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.common-stock | 0 | 68.6 | 68.6 | 68.3 | ||||||||||
balance-sheet.row.retained-earnings | 0 | 438.4 | 349.1 | 344.3 | ||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 1588.9 | 34.8 | 58.1 | ||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | -469.2 | 1076 | 1062.3 | ||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 1626.8 | 1528.5 | 1533.1 | ||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 1806 | 1684.2 | 1638.7 | ||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | ||||||||||
balance-sheet.row.total-equity | 0 | 1626.8 | 1528.5 | 1533.1 | ||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | ||||||||||
Total Investments | 0 | 22 | 0 | 0.8 | ||||||||||
balance-sheet.row.total-debt | 0 | 0 | 1.2 | 3 | ||||||||||
balance-sheet.row.net-debt | 0 | -1155 | -1246.9 | -1363 |
Kassavirtalaskelma
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 93.8 | 177.5 | 143.1 | |||||||||
cash-flows.row.depreciation-and-amortization | 0 | 17.1 | 11.1 | 8.8 | |||||||||
cash-flows.row.deferred-income-tax | 0 | 2.3 | -8.1 | -1.1 | |||||||||
cash-flows.row.stock-based-compensation | 0 | -2.8 | 21.4 | 1.1 | |||||||||
cash-flows.row.change-in-working-capital | 0 | -8.7 | -33.5 | -19.1 | |||||||||
cash-flows.row.account-receivables | 0 | 7.3 | -13.1 | -15.9 | |||||||||
cash-flows.row.inventory | 0 | 1.8 | 6.7 | -5.6 | |||||||||
cash-flows.row.account-payables | 0 | -20.1 | -19 | 3.4 | |||||||||
cash-flows.row.other-working-capital | 0 | 2.3 | -8.1 | -1.1 | |||||||||
cash-flows.row.other-non-cash-items | 0 | -15.6 | -11 | -12.1 | |||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -95.6 | -87.3 | -11.7 | |||||||||
cash-flows.row.acquisitions-net | 0 | -34.2 | 0 | 11.7 | |||||||||
cash-flows.row.purchases-of-investments | 0 | -3648 | -4264 | -2102.4 | |||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 3664 | 4284.6 | 2115.8 | |||||||||
cash-flows.row.other-investing-activites | 0 | 9 | -10 | -11.7 | |||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -104.8 | -76.8 | 1.9 | |||||||||
cash-flows.row.debt-repayment | 0 | -2 | -1.3 | -14 | |||||||||
cash-flows.row.common-stock-issued | 0 | 16.9 | -0.3 | -18 | |||||||||
cash-flows.row.common-stock-repurchased | 0 | -14.9 | 1.6 | 18 | |||||||||
cash-flows.row.dividends-paid | 0 | -88.9 | -71.8 | -50.3 | |||||||||
cash-flows.row.other-financing-activites | 0 | -6.1 | -9.2 | 1059.1 | |||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | -95 | -81 | 994.8 | |||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||
cash-flows.row.net-change-in-cash | 0 | -113.6 | -0.4 | 1117.4 | |||||||||
cash-flows.row.cash-at-end-of-period | 0 | 1247.7 | 1361.3 | 1361.7 | |||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 1361.3 | 1361.7 | 244.4 | |||||||||
cash-flows.row.operating-cash-flow | 0 | 86.2 | 157.4 | 120.8 | |||||||||
cash-flows.row.capital-expenditure | 0 | -95.6 | -87.3 | -11.7 | |||||||||
cash-flows.row.free-cash-flow | 0 | -9.4 | 70 | 109.1 |
Tuloslaskelmarivi
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 462.2 | 321.6 | 430 | ||||||||||
income-statement-row.row.cost-of-revenue | 0 | 130.5 | 88.5 | 108.5 | ||||||||||
income-statement-row.row.gross-profit | 0 | 331.7 | 233.1 | 321.6 | ||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.other-expenses | 0 | 1.6 | 18 | 7.4 | ||||||||||
income-statement-row.row.operating-expenses | 0 | 208.7 | 162.9 | 163.1 | ||||||||||
income-statement-row.row.cost-and-expenses | 0 | 339.2 | 251.4 | 271.6 | ||||||||||
income-statement-row.row.interest-income | 0 | 19.3 | 19.3 | 16.8 | ||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.3 | 0.2 | ||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 1.6 | 1.4 | 2.7 | ||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.other-operating-expenses | 0 | 1.6 | 18 | 7.4 | ||||||||||
income-statement-row.row.total-operating-expenses | 0 | 1.6 | 1.4 | 2.7 | ||||||||||
income-statement-row.row.interest-expense | 0 | 1.3 | 0.3 | 0.2 | ||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 20.1 | 19.5 | 14.9 | ||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||
income-statement-row.row.operating-income | 0 | 148.4 | 104.5 | 194.7 | ||||||||||
income-statement-row.row.income-before-tax | 0 | 150 | 105.8 | 197.4 | ||||||||||
income-statement-row.row.income-tax-expense | 0 | 13.8 | 12 | 19.8 | ||||||||||
income-statement-row.row.net-income | 0 | 136.3 | 93.8 | 177.8 |
Usein kysytty kysymys
Mikä on Nanjing Vishee Medical Technology Co., Ltd (688580.SS) taseen loppusumma?
Nanjing Vishee Medical Technology Co., Ltd (688580.SS) kokonaisvarat ovat 1806024041.000.
Mikä on yrityksen vuotuinen liikevaihto?
Vuotuinen liikevaihto on N/A.
Mikä on yrityksen voittomarginaali?
Yrityksen voittomarginaali on 0.715.
Mikä on yrityksen vapaa kassavirta?
Vapaa kassavirta on -0.334.
Mikä on yrityksen nettovoittomarginaali?
Nettovoittomarginaali on 0.282.
Mikä on yrityksen kokonaistulot?
Kokonaisliikevaihto on 0.306.
Mikä on Nanjing Vishee Medical Technology Co., Ltd (688580.SS) nettovoitto (nettotulos)?
Nettovoitto (nettotulos) on 136258629.000.
Mikä on yrityksen kokonaisvelka?
Kokonaisvelka on 0.000.
Mikä on yrityksen toimintakulujen määrä?
Toimintakulut ovat 208672734.000.
Mikä on yrityksen kassan määrä?
Yrityksen kassavarat ovat 0.000.